Genus Lifesciences Drug Patent Portfolio
Genus Lifesciences owns 2 orange book drugs protected by 7 US patents Given below is the list of Genus Lifesciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231931 | Thyroid hormone oral dosage forms and methods of using the same | 23 Mar, 2038 | Active |
| US10406108 | Thyroid hormone oral dosage forms and methods of using the same | 23 Mar, 2038 | Active |
| US9539214 | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid | 13 Mar, 2033 | Active |
| US9987231 | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid | 02 Jan, 2033 | Active |
| US6926907 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | 28 Feb, 2023 | Expired |
| US8206741 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | 28 Feb, 2023 | Expired |
| US9364439 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | 31 May, 2022 | Expired |
Latest Legal Activities on Genus Lifesciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Genus Lifesciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 12 Feb, 2024 | US8206741 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Mar, 2023 | US10406108 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2022 | US10231931 |
|
Expire Patent
Critical
| 11 Jul, 2022 | US9987231 |
|
Maintenance Fee Reminder Mailed
Critical
| 24 Jan, 2022 | US9987231 |
| Surcharge for Late Payment, Large Entity | 10 Sep, 2020 | US9539214 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Sep, 2020 | US9539214 |
|
Maintenance Fee Reminder Mailed
Critical
| 31 Aug, 2020 | US9539214 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Dec, 2019 | US8206741 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 Sep, 2019 | US10406108 |
|
Recordation of Patent Grant Mailed
Critical
| 10 Sep, 2019 | US10406108 |
|
Application ready for PDX access by participating foreign offices
Critical
| 10 Sep, 2019 | US10406108 |
|
Email Notification
Critical
| 22 Aug, 2019 | US10406108 |
|
Issue Notification Mailed
Critical
| 21 Aug, 2019 | US10406108 |
| Dispatch to FDC | 07 Aug, 2019 | US10406108 |
Genus Lifesciences's Drug Patent Litigations
Genus Lifesciences's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 21, 2015, against patent number US6926907. The petitioner Coalition for Affordable Drugs VII LLC, challenged the validity of this patent, with POZEN Inc. as the respondent. Click below to track the latest information on how companies are challenging Genus Lifesciences's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6926907 | May, 2015 |
Terminated-Denied
(08 Dec, 2015)
| POZEN Inc. | Coalition for Affordable Drugs VII LLC |
Genus Lifesciences Drug Patents' Oppositions Filed in EPO
Genus Lifesciences drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 15, 2011, by Strawman Limited. This opposition was filed on patent number EP02734602A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP02734602A | Apr, 2011 | CHATFIELD PHARMACEUTICALS LIMITED | Patent maintained as amended |
| EP02734602A | Apr, 2011 | STRAWMAN LIMITED | Patent maintained as amended |
Genus Lifesciences's Family Patents
Genus Lifesciences Drug List
Given below is the complete list of Genus Lifesciences's drugs and the patents protecting them.
1. Levolet
Levolet is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231931 | Thyroid hormone oral dosage forms and methods of using the same |
23 Mar, 2038
(13 years from now)
| Active |
| US10406108 | Thyroid hormone oral dosage forms and methods of using the same |
23 Mar, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levolet's drug page
2. Yosprala
Yosprala is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9539214 | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
13 Mar, 2033
(8 years from now)
| Active |
| US9987231 | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
02 Jan, 2033
(8 years from now)
| Active |
| US6926907 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
28 Feb, 2023
(1 year, 7 months ago)
| Expired |
| US8206741 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
28 Feb, 2023
(1 year, 7 months ago)
| Expired |
| US9364439 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
31 May, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yosprala's drug page